Exondys 51 Market Report 2026

Exondys 51 Market Overview

• The Exondys 51 market growth in the historic period has been driven by lack of curative dmd therapies, historical reliance on supportive care • Market expansion is supported by advancements in molecular genetics, expansion of personalized neuromuscular care • Growth Driver: Rising Burden Of Genetic Disorders Driving Growth In The Market • Market Trend: Enhanced Safety Monitoring and Label Refinement in the Exondys 51/ELEVIDYS Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Exondys 51 Market?

Exondys 51 (eteplirsen) is a medication used to treat duchenne muscular dystrophy (DMD) by promoting exon-skipping of the dystrophin gene, allowing the production of a functional but shortened dystrophin protein. Exondys 51 works by skipping over exon 51 of the dystrophin gene, allowing the production of a shortened but functional version of the dystrophin protein. The main types of indications in exondys 51 are relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), and other multiple sclerosis forms. Relapsing-remitting multiple sclerosis (RRMS) refers to the most common form of multiple sclerosis, characterized by clearly defined relapses or attacks of neurological symptoms. It is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies, and applications include subcutaneous injection, long-term disease management, and prophylactic use.

What Is The Exondys 51 Market Growth Forecast?

The growth in the forecast period can be attributed to advancements in molecular genetics, expansion of personalized neuromuscular care, rising newborn screening initiatives, increased research funding for dmd, growing specialty neurology centers. Major trends in the forecast period include growth of exon skipping therapies, expansion of targeted dmd treatments, rising adoption of genetic based medicines, focus on slowing disease progression, increasing long term therapy management.

Global Exondys 51 Market Segmentation

1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies 3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use

What Are The Drivers Of The Exondys 51 Market?

The rising burden of genetic disorders is expected to propel the growth of the exondys 51 market going forward. Genetic disorders refer to conditions that are caused by abnormalities or mutations in an individual's DNA or genetic material. The rising burden of genetic disorders can be attributed to several factors, including advancements in medical technology, changes in demographics, and improvements in diagnosis and awareness. Exondys 51 (eteplirsen) treats genetic disorders by enabling exon 51 skipping in the dystrophin gene, allowing the production of a functional, though shortened, dystrophin protein to slow muscle degeneration. For instance, in July 2024, according to the National Health Service, a UK-based government department, approximately 70,000 individuals are affected by muscular dystrophy (MD) or a related condition in the UK, with Duchenne MD being the most prevalent form. Each year, around 100 boys are diagnosed with Duchenne MD, and approximately 2,500 people in the UK are living with the condition at any given time. Therefore, the rising burden of genetic disorders is driving the growth of the exondys 51 industry. Rising investments in healthcare are expected to boost the growth of the exondys 51 market going forward. Healthcare investments refer to the allocation of financial resources toward entities, technologies, services, or innovations in the healthcare sector. Healthcare investments are rising due to increasing demand for chronic disease management from aging populations and funding for advanced technologies such as telemedicine to improve healthcare delivery. Healthcare investments drive exondys 51 by funding research, clinical trials, and technologies such as exon-skipping, which enable the treatment of duchenne muscular dystrophy and improve patient access through programs and infrastructure support. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, marking a significant rise compared to the 0.9% growth seen in 2022. Therefore, rising investments in healthcare are driving the growth of the exondys 51 industry.

Key Players In The Global Exondys 51 Market

Major companies operating in the exondys 51 market are Sarepta Therapeutics

Global Exondys 51 Market Trends and Insights

Major companies operating in the exondys 51 market are focusing on enhancing safety and refining patient selection, such as updating prescribing information for ELEVIDYS to mitigate liver-related risks and ensure appropriate patient eligibility. ELEVIDYS refers to Sarepta Therapeutics’ AAV-based micro-dystrophin gene therapy (delandistrogene moxeparvovec) designed to restore dystrophin expression in patients with Duchenne muscular dystrophy (DMD). For instance, in November 2025, the U.S. FDA, a US-based federal agency, approved an updated label for ELEVIDYS, adding a boxed warning for acute serious liver injury and acute liver failure and limiting its use to ambulatory patients aged four years and older. The update introduces mandatory weekly liver-function testing for the first three months post-infusion, requires corticosteroid pre- and post-dosing, and advises patients to remain near a qualified healthcare facility for at least two months, all aimed at improving safety monitoring and patient outcomes.

Regional Insights

North America was the largest region in the exondys 51 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Exondys 51 Market?

The exondys 51 market consists of sales of products including golodirsen (Vyondys 53), viltolarsen (Viltepso), and casimersen (Amondys 45). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Exondys 51 Market Report 2026?

The exondys 51 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the exondys 51 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.